BACKGROUND: Little has been reported on costs of cancer registration, and standard indicators have not yet been identified. This study investigated costs and outcomes of a sample of 18 European registries covering a population of 58.8 million inhabitants. METHODS: Through a questionnaire, we asked registries for real cost data including personnel, information technology (IT), and infrastructure. Staff costs were grouped by professional position and by activity performed. As outcomes, besides the production of current data, we considered publications in peer-reviewed journals (last 5 years' impact factor [IF]) and characteristics of registry websites. RESULTS: In our sample, the average cost of cancer registration per inhabitant w...
PURPOSE: Targeted cancer therapies (TCTs) are drugs that specifically act on molecular targets withi...
Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs wi...
Economic constraints are a reality in the European healthcare environment. Because it is impossible ...
BACKGROUND: Little has been reported on costs of cancer registration, and standard indicators hav...
BACKGROUND: Little has been reported on costs of cancer registration, and standard indicators have n...
AIM: To provide insight into cancer registration coverage, data access and use in Europe. This contr...
Aim To provide insight into cancer registration coverage, data access and use in Europe. This contri...
Background: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
BACKGROUND: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
Background: There are several national cancer registries available across Europe, but information on...
Background: There are several national cancer registries available across Europe, but information on...
Population-based cancer registries (CRs) in Europe have played a supportive, sometimes guiding, role...
Background In 2008, 2.45 million people were diagnosed with cancer and 1.23 million died because of...
Objective: To determine the economic burden of colorectal cancer (CRC) across Europe. Design: Activ...
ContextThe Centers for Disease Control and Prevention evaluated the economics of the National Progra...
PURPOSE: Targeted cancer therapies (TCTs) are drugs that specifically act on molecular targets withi...
Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs wi...
Economic constraints are a reality in the European healthcare environment. Because it is impossible ...
BACKGROUND: Little has been reported on costs of cancer registration, and standard indicators hav...
BACKGROUND: Little has been reported on costs of cancer registration, and standard indicators have n...
AIM: To provide insight into cancer registration coverage, data access and use in Europe. This contr...
Aim To provide insight into cancer registration coverage, data access and use in Europe. This contri...
Background: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
BACKGROUND: In 2008, 2·45 million people were diagnosed with cancer and 1·23 million died because of...
Background: There are several national cancer registries available across Europe, but information on...
Background: There are several national cancer registries available across Europe, but information on...
Population-based cancer registries (CRs) in Europe have played a supportive, sometimes guiding, role...
Background In 2008, 2.45 million people were diagnosed with cancer and 1.23 million died because of...
Objective: To determine the economic burden of colorectal cancer (CRC) across Europe. Design: Activ...
ContextThe Centers for Disease Control and Prevention evaluated the economics of the National Progra...
PURPOSE: Targeted cancer therapies (TCTs) are drugs that specifically act on molecular targets withi...
Background: Rising expenditure for new cancer medicines is accelerating concerns that their costs wi...
Economic constraints are a reality in the European healthcare environment. Because it is impossible ...